MedTrace Logo

Low-FODMAP vs Gluten-Free Diet in Irritable Bowel Syndrome

NCT07800650 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-09-02

No results posted yet for this study

Summary

Irritable Bowel Syndrome (IBS) is a common functional gastrointestinal disorder characterized by recurrent abdominal pain and irregular bowel habits. Dietary interventions, particularly low-FODMAP and gluten-free diets, have gained increasing interest in IBS management. However, comparative data on these two approaches remain limited across different populations, including the Turkish population. This study was designed to compare the effectiveness of a 4-week low-FODMAP diet versus a gluten-free diet on gastrointestinal symptoms in Turkish patients with IBS.

A total of 70 patients diagnosed with IBS according to Rome IV criteria were enrolled in this prospective, controlled, parallel-group clinical trial. Patients were sequentially assigned to either the low-FODMAP group (n=35) or the gluten-free diet group (n=35). Both dietary interventions were implemented over 4 weeks under the guidance of an experienced dietitian, with weekly telephone follow-ups to monitor dietary compliance. Gastrointestinal symptoms were evaluated at baseline and at the end of the intervention using the Gastrointestinal Symptom Rating Scale (GSRS).

Conditions

  • Irritable Bowel Syndrome

Interventions

OTHER

Low-FODMAP Diet

Participants were instructed to limit foods high in FODMAPs (onions, garlic, pulses, certain fruits and vegetables, wheat products) and to consume low-FODMAP alternatives (rice, oats, potatoes, carrots, bananas). The diet was applied for 4 weeks.

OTHER

Gluten-Free Diet

Participants were instructed to exclude gluten-containing grains (wheat, barley, rye) and their derivatives (bread, pasta, pastries), and to consume naturally gluten-free foods (rice, corn, potatoes, meat, vegetables, fruits). The diet was applied for 4 weeks.

Sponsors & Collaborators

  • Ertuğrul Çoruh

    lead OTHER

Principal Investigators

  • Ertuğrul Çoruh, MD · Yıldızkent Family Health Center, Palandöken District Health Directorate, Erzurum, Turkey

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-24
Primary Completion
2026-07-20
Completion
2026-07-25

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07800650 on ClinicalTrials.gov